PMEF
ATRA icon

Point72 Middle East FZE’s Atara Biotherapeutics ATRA Stock Holding History

Point72 Middle East FZE’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,421
Closed -$18.2K – 127
2023
Q4 		$18.2K Buy
+1,421
New +$33.1K ﹤0.01% 1365
2023
Q3 		– Sell
-1,014
Closed -$40.8K – 1444
2023
Q2 		$40.8K Buy
+1,014
New +$57.3K ﹤0.01% 1319
2023
Q1 		– Sell
-1,389
Closed -$114K – 1633
2022
Q4 		$114K Buy
+1,389
New +$145K 0.01% 1229

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Middle East FZE's ATRA Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 1,421 shares — an estimated $18.2K sold.

Point72 Middle East FZE first reported a position in ATRA in Q4 2022 and held it in 3 quarters. The position peaked at $114K in Q4 2022. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,421 Atara Biotherapeutics shares in Q1 2024, an estimated $18.2K.
  • Point72 Middle East FZE first reported a position in Atara Biotherapeutics in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Atara Biotherapeutics position peaked at $114K in Q4 2022.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.